This suggests that downregulation of NEU1 is a therapeutic strategy for NSCLC, which is not contrary to our view of NEU1 inhibitors as a co-administration strategy for sotorasib cardiotoxicity. The gene discussed is NEU1; the disease is non-small cell lung carcinoma.